Literature DB >> 23040908

Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder.

Brigette Vaughan1, Christopher J Kratochvil.   

Abstract

This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23040908     DOI: 10.1016/j.chc.2012.07.005

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  12 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

Review 2.  Treatment of clozapine-associated weight gain: a systematic review.

Authors:  Z Whitney; R M Procyshyn; D H Fredrikson; A M Barr
Journal:  Eur J Clin Pharmacol       Date:  2015-01-28       Impact factor: 2.953

Review 3.  Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Authors:  Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-12-08       Impact factor: 3.921

4.  Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.

Authors:  Mark L Wolraich; Joseph F Hagan; Carla Allan; Eugenia Chan; Dale Davison; Marian Earls; Steven W Evans; Susan K Flinn; Tanya Froehlich; Jennifer Frost; Joseph R Holbrook; Christoph Ulrich Lehmann; Herschel Robert Lessin; Kymika Okechukwu; Karen L Pierce; Jonathan D Winner; William Zurhellen
Journal:  Pediatrics       Date:  2019-10       Impact factor: 7.124

5.  Expanding medication options for pediatric ADHD.

Authors:  Tanya E Froehlich; Sergio V Delgado; Julia S Anixt
Journal:  Curr Psychiatr       Date:  2013-12

6.  Atomoxetine-induced mydriasis in a child patient.

Authors:  Kayhan Bahali; Hamiyet Ipek; Ozhan Yalcin; Ozgur Orum
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-11-09       Impact factor: 4.785

7.  Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.

Authors:  Yin-To Liao; Yao-Hsu Yang; Ting-Yu Kuo; Hsin-Yi Liang; Kuo-You Huang; Tsu-Nai Wang; Yena Lee; Roger S McIntyre; Vincent Chin-Hung Chen
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-08-30       Impact factor: 4.785

8.  A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.

Authors:  James Ermer; Mary Corcoran; Kenneth Lasseter; Thomas Marbury; Brian Yan; Patrick T Martin
Journal:  Ther Drug Monit       Date:  2016-08       Impact factor: 3.681

9.  Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study.

Authors:  Vincent Chin-Hung Chen; Yao-Hsu Yang; Charles Tzu-Chi Lee; Yi-Lung Chen; Michael E Dewey; Michael Gossop
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-01-02       Impact factor: 4.785

10.  Spontaneous Ejaculation Induced with Atomoxetine.

Authors:  Ferhat Yaylacı; Begüm Şahbudak; Önder Küçük
Journal:  Psychopharmacol Bull       Date:  2020-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.